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A possible impact of the neuroD2 transcription factor on the development of drug abusing behavior A recent study by Lin et al. 1 has shown that the transcription factor neuroD2 regulates amygdala development and emotional learning in mice. In neuroD2-null mice, the lateral and basolateral amygdala was undeveloped and neuroD2 heterozygous mice had fewer neurons in this region. Moreover, neuroD2 heterozygous mice revealed a profound deficit in emotional learning when compared to wildtype controls in terms of decreased anxiety behaviors in unconditioned fear tests. The present results of a post-mortem mRNA expression study of the neuroD2 gene in human brain suggest that the neuroD2 gene might be one of the crucial factors in the development of drug abusing behavior in humans.
NeuroD2 is a basic helix-loop-helix transcription factor with important functions during development of the nervous system. 2 In adult central nervous system (CNS), sustained neuroD2 mRNA expression is detected in specific brain regions, including the hippocampus, cortex and cerebellum. 3 Lin et al. could demonstrate that neuroD2 is necessary not only for the amygdala development in mice but also that the dose of the neuroD2 gene is critical for the regulation of molecules that underlie emotional learning, as the AMPA receptor, the gamma aminobutyric acid (GABA)-A receptor and Ulip, a protein that is involved in neuronal plasticity. 1 Furthermore, neuroD2 heterozygous mice showed a decreased response to fear conditioning and unconditioned fear analysis. 1 There is increasing evidence that addiction not only emerges from neuronal mechanisms of learning and memory, with involvement of the GABAergic and glutamatergic systems, but also represents a risktaking behavior itself. [4] [5] [6] Additionally, suicidal behavior has a high comorbidity with risk-related personality traits, with the highest risk-taking behavior in completed suicide by violent means. 7 These results suggest that the neuroD2 gene might also control risktaking behaviors in humans. Therefore, we performed a post-mortem mRNA expression study of the neuroD2 gene in the human brain tissue cortex, hippocampus, amygdala and hypothalamus of drug abusers, suicide victims and controls.
Brain specimens were obtained during routine autopsy at the Institute for Legal Medicine of the Ludwig-Maximilians-University Munich and derived from 11 individuals who died as a consequence of an opiate dependence (nine men, two women, mean age 31.277.6 years; post-mortem interval (PMI): 16.475.2 h) and from nine suicide victims (six men three women, mean age 44.5715.0 years; PMI: 20.178.4 h). Six of them have committed violent suicides, for example, hanging (n = 2), penetrating lesions (n = 3) and jumping from height (n = 1), and three were employing so-called soft suicide methods, such as intoxication with drugs or other substances. The control tissues were obtained from 16 persons who died suddenly from diseases not directly involving the CNS. The causes of the deaths were the following: acute cardiac failure (n = 7), accident (n = 3) and homicide (n = 6). The clinical, respective, medical data sheets of the control individuals were available to the Institute for Legal Medicine of the Ludwig-Maximilians-University Munich, and did not give any hint on lifetime psychiatric or neurological disorders. According to the medical records, there was no history of psychopharmacological medication, alcohol or drug abuse. Additionally a toxicological report for all individuals was provided, whereas informations on pre-existing psychiatric disturbances were missing for the suicide victims. All individuals were Caucasians from the same geographical region in southern Germany.
Sections were taken from the orbitofrontal cerebral cortex, the posterior hippocampus at the coronal level of the lateral geniculate nucleus, the amygdala and the hypothalamus. The tissue probes were collected using the RNAlater kit (Qiagen, Hilden, Germany) to avoid degradation of the RNA and were immediately frozen at À801C until being used for the RNA extraction. Total RNA extraction, DNase treatment and cDNA synthesis was performed according to standard procedures.
Quantitative real-time polymerase chain reaction (PCR) experiments were carried out on the ABI 7000 Sequence Detection System (Taqman) (Applied Biosystems, Foster City, USA) with a commercially available assay on demand for the neuroD2 gene (ordering number: hs00272055_s1; Applied Biosystems). The tissue probes studied had been matched for mRNA stability by using the housekeeping gene ribosomal phosphoprotein large P0 (RPLP0). The amount of amplified PCR products was calculated with mRNA of total brain tissue as calibrator.
Comparison of the different groups was performed by the one-way analysis of variance test using SPSS for Windows (Version 12.0; SPSS, Chicago, IL, USA). Figure 1 shows the individual neuroD2 mRNA levels in the investigated brain regions for each group as scatter plot. The highest mRNA levels compared to total brain tissue as calibrator were detected in the hippocampus, followed by the cortex and amygdala, whereas negligible amounts were found in the hypothalamus. In the hippocampus as well as in the cortex, the drug abusers had significant lower neuroD2 mRNA levels than those of the controls (hippocampus: P = 0.005, F = 9.5, df = 1; cortex: P = 0.006, F = 8.9, df = 1) and the suicide victims (hippocampus: P = 0.02, F = 7.0, df = 1; cortex: P = 0.03, F = 5.4, df = 1). In the cortex, only one suicide victim revealed an mRNA level over 2.0. After removal of this probe from the analysis, the difference between drug abusers and suicide victims was no longer significant. In the amygdala and hypothalamus, we could not find any significant differences between the investigated samples. Furthermore, in the cortex and hippocampus, the neuroD2 mRNA levels of suicide victims and controls were also in a similar range.
The results of our study suggest that the neuroD2 gene might represent a risk factor for the development of drug-abusing behavior. We found significant lower neuroD2 mRNA levels in the group of opiatedependent individuals in the cortex and hippocampus, two brain regions that are of major interest in addiction research. Although the major part of the reward system in addiction is the dopaminergic projection from the ventral tegmental area (VTA) to the nucleus accumbens (NAS), also dopaminergic projections from the VTA to the cortex, as well as massive glutamatergic inputs to the VTA from the cortex, hippocampus and amygdala are involved in the mediation of reward. 5 Interestingly, these structures and neurotransmitter systems have been implicated in aspects of reward evaluation, learning and memory 8 characteristics that have been reported by Lin et al.
1 as being associated with the neuroD2 gene. Diminished neuroD2 levels are related not only to decreased amounts of the AMPA and GABA-A receptors in mice but also to an increased risk behavior. In this context, our results seem to be in concordance with these functional consequences. Lower amounts of the neuroD2 gene in drug abusers might also lead to lower GABA-A receptor levels and consequently higher dopaminergic activity, to lower amounts of AMPA receptors, which influence the glutamatergic systems, including learning and memory processes, and finally to diminished anxiety, which will be obvious by the risk-taking behavior of drug-dependent patients.
Interestingly, we could not observe any differences in the neuroD2 mRNA levels in the amygdala, where the original finding by Lin et al. has been reported. This result suggests that brain structures other than the amygdala (e.g. cortex, hippocampus) might have a greater impact on the development of addiction behavior. Furthermore, no relation was detectable between the neuroD2 gene and suicidal behavior. This observation implicates that other neurobiological mechanisms independent from the neuroD2 gene, as serotonergic mechanisms, contribute rather to suicidal behavior.
The effects of PMI, tissue pH and prolonged agonal states on mRNA stability are well known as limiting factors in post-mortem expression studies. Previous reports revealed that age at death and brain pH are potential confounders in studies using postmortem brain tissues, whereas no correlation was observed with agonal states and also PMI were seen to have minimal influence on mRNA levels. 9 The PMI of the investigated brain samples were in the range between 6 and 32 h; no information about the agonal states was available, but while considering recent studies, these factors seem not to play an important role. 9 Unfortunately, during the routine autopsies, the pH levels of the brain tissues were not determined. It has been shown that there is a non-random degradation of mRNA following death, but these inter-individual differences can be explained and removed by normalization with a housekeeping gene, 10 a method that was applied in the present study. Finally, although the average PMI in the group of suicide victims was 4 h longer than in the drug abusers (20.1 vs 16.2 h), the suicide group showed higher mRNA levels. Therefore, we can exclude to a great extent confounding factors in our analysis. It has to be mentioned that it is finally difficult to conclude whether the reduced neuroD2 mRNA expression is causally involved in the development of drug-abusing behavior or whether the decline of neuroD2 mRNA is secondary to the effects of the consumed opioids. Nonetheless, the decrease of neuroD2 mRNA might be a possible candidate mechanism in sustaining addiction.
In summary, this is the first report about a relation between the neuroD2 transcription factor and drugabusing behavior in humans. The interpretations of our results are still speculative and need further examination, but the findings might represent a new approach in addiction research. 
